Treatment of juxta-anastomotic stenoses for failing distal radiocephalic arteriovenous fistulas: Drug-coated balloons versus angioplasty

Abstract

The aim of our study is to report the results of two types (type A, type B) paclitaxel drug-coated balloon compared with standard percutaneous transluminal angioplasty in the treatment of juxta-anastomotic stenoses of mature but failing distal radiocephalic hemodialysis arteriovenous fistulas. Two groups of 26 and 44 patients treated with two different drug-coated balloon are compared with a control group of 86 treated with standard percutaneous transluminal angioplasty. A color Doppler ultrasound was performed to evaluate stenosis and for treatment planning. We assess primary patency, defined as the absence of dysfunction of the arteriovenous fistulas, patent lesion or residual stenosis < 30% and no need for further reintervention of target lesion. Primary patency and secondary patency are evaluated after 12 months with color Doppler ultrasound for the whole arteriovenous fistulas, defined as absolute (absolute primary patency, absolute secondary patency) and target lesion. Postprocedural technical and clinical success was 100%. After 12 months, absolute primary patency is 81.8% for type A, 84.1% type B, and 54.7% for standard percutaneous transluminal angioplasty; target lesion primary patency is 92% type A, 86.4% type B, and 62.8% standard percutaneous transluminal angioplasty; absolute secondary patency is 95.4% type A, 95.5% type B, and 80.7% standard percutaneous transluminal angioplasty; target lesion secondary patency is 100% type A, 97.7% type B, and 80.7% standard percutaneous transluminal angioplasty. All the patients treated with drug-coated balloon (type A + type B) have an absolute primary patency of 83.3%, a target lesion primary patency of 87.9%, an absolute secondary patency of 95.5%, and a target lesion secondary patency of 98.4%. Our study confirms that the use of drug-coated balloon, indiscriminately among different brands, improves primary patency with statistically significant difference in comparison with standard percutaneous transluminal angioplasty and decreases reintervention of target lesion in juxta-anastomotic stenoses of failing distal arteriovenous fistulas maintaining the radiocephalic fistula as long as possible.

Keywords

Paclitaxel eluting ballons standard angioplasty stenosis juxta-anastomotic region distal radiocephalic fistulas

Get full access to this article

View all access options for this article.

References

De Nicola

Zoccali

. Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant 2016; 31(3): 331–335.

Bruck

Stel

Gambaro

et al . CKD prevalence varies across the European general population. J Am Soc Nephrol 2016; 27(7): 2135–2147.

De Nicola

Donfrancesco

Minutolo

et al . Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrol Dial Transplant 2015; 30(5): 806–814.

Mori

Horikawa

Kazuyuki

et al . Stenotic lesions in vascular access: treatment with transluminal angioplasty using high-pressure balloons. Intern Med 1994; 33(5): 284–287.

Patanè

Morale

Malfa

et al . Trattamento endovascolare delle complicanze steno-ostruttive delle fistole artero-venose emodialitiche: nuovi aspetti di intervento con radiologia interventistica. Giorn Italian Nefrol 2009; 26: 236–245, http://www.nephromeet.com/web/eventi/GIN/dl/storico/2009/2/236-245.pdf (accessed 5 September 2016).

Manninen

Kaukanen

Ikäheimo

et al . Brachial arterial access: endovascular treatment of failing Brescia-Cimino hemodialysis fistulas –initial success and long-term results. Radiology 2001; 218(3): 711–718.

Bhimani

Asif

Diagnosis and salvage of an immature fistula. Kidney Int 2007; 72: 126–130.

Patanè

Giuffrida

Morale

et al . Drug-eluting balloon for the treatment of failing hemodialytic radiocephalic arteriovenous fistulas: our experience in the treatment of juxta-anastomotic stenoses. J Vasc Access 2014; 15(5): 338–343.

Long

Brichart

Lermusiaux

et al . Management of perianastomotic stenosis of direct wrist autogenous radial-cephalic arteriovenous accesses for dialysis. J Vasc Surg 2011; 53(1): 108–114.

10.

Rotmans

JI.

Sirolimus-eluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: a 4-week follow-up study. Circulation 2005; 111(12): 1537–1542.

11.

Lee

BH.

Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol Dial Transplant 2006; 21(9): 2432–2438.

12.

Kohler

Toleikis

Gravett

et al . Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable vascular wrap (vascular wrap is a trademark of Angiotech Pharmaceuticals, Inc.) paclitaxel-eluting mesh. J Vasc Surg 2007; 45(5): 1029–1038.e3.

13.

Roy-Chaudhury

Endothelial progenitor cells, neointimal hyperplasia, and hemodialysis vascular access dysfunction: novel therapies for a recalcitrant clinical problem. Circulation 2005; 112(1): 3–5.

14.

Roy-Chaudhury

Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 2006; 17(4): 1112–1127.

15.

Roy-Chaudhury

Kelly

Miller

et al . Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59(6): 2325–2334.

16.

Terry

Shiu

Y-TE

et al . Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int 2008; 74(10): 1247–1261.

17.

Bharat

Jaenicke

Shenoy

A novel technique of vascular anastomosis to prevent juxta-anastomotic stenosis following arteriovenous fistula creation. J Vasc Surg 2012; 55: 274–280.

18.

Sadaghianloo

Declemy

Jean-Baptiste

et al . Radial artery deviation and reimplantation inhibits venous juxta-anastomotic stenosis and increases primary patency of radial-cephalic fistulas for hemodialysis. J Vasc Surg 2016; 64: 698–706.e1.

19.

Diskin

Stokes

TJJ

Pennell

AT.

Pharmacologic Intervention to prevent hemodialysis vascular access thrombosis. Nephron 1993; 64(1): 1–26.

20.

Sreedhara

Himmelfarb

Lazarus

et al . Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477–1483.

21.

Schmitz

McCloud

Reikes

et al . Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 2002; 13(1): 184–190.

22.

Gradzki

Dhingra

Port

et al . Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38(6): 1240–1244.

23.

Kelly

Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant 2006; 21(9): 2425–2431.

24.

Allon

Current management of vascular access. Clin J Am Soc Nephrol 2007; 2(4): 786–800.

25.

Roy-Chaudhury

Kelly

Zhang

et al . Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. Blood Purif 2003; 21(1): 99–110.

26.

III . NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1): S137–S181.

27.

Tonnessen

Money

SR.

Embracing the fistula first national vascular access improvement initiative. J Vasc Surg 2005; 42(3): 585–586.

28.

Terry

Kim

S-E

et al . Longitudinal assessment of hyperplasia using magnetic resonance imaging without contrast in a porcine arteriovenous graft model. Acad Radiol 2009; 16(1): 96–107.

29.

Schwab

SJ.

Vascular access for hemodialysis. Kidney Int 1999; 55(5): 2078–2090.

30.

Turmel-Rodrigues

Dilatation is usually the best treatment for stenosis of the arteriovenous hemodialysis fistula. Nat Clin Pract Nephrol 2008; 4(3): 116–117.

31.

Remuzzi

Ene-Iordache

Mosconi

et al . Radial artery wall shear stress evaluation in patients with arteriovenous fistula for hemodialysis access. Biorheology 2003; 40(1–3): 423–430.

32.

Corpataux

Haesler

Silacci

Low-pressure environment and remodelling of the forearm vein in Brescia-Cimino haemodialysis access. Nephrol Dial Transplant 2002; 17(6): 1057–1062.

33.

Roy-Chaudhury

Wang

Krishnamoorthy

et al . Cellular phenotypes in human stenotic lesions from haemodialysis vascular access. Nephrol Dial Transplant 2009; 124(9): 2786–2791.

34.

Wang

Krishnamoorthy

Banerjee

et al . Venous stenosis in a pig arteriovenous fistula model—anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant 2007; 23(2): 525–533.

35.

Terry

Blumenthal

et al . Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant 2007; 22(11): 3139–3146.

36.

Roy-Chaudhury

Arend

Zhang

et al . Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis 2007; 50(5): 782–790.

37.

Suzuki

Kopia

Hayashi

et al . Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104(10): 1188–1193.

38.

Heldman

Cheng

Jenkins

et al . Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103(18): 2289–2295.

39.

Morice

M-C

Serruys

Sousa

et al . A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773–1780.

40.

Stone

Ellis

Cox

et al . A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350(3): 221–231.

41.

Sousa

JE.

Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005; 111(18): 2326–2329.

42.

Kałuża

Gershlick

Park

S-J

et al . Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials). Am J Cardiol 2004; 94(2): 199–201.

43.

Gershlick

Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109(4): 487–493.

44.

Büllesfeld

Gerckens

Müller

et al . Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. Z Für Kardiol 2003; 92(10): 825–832.

45.

Stone

GW.

One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109(16): 1942–1947.

46.

Ferraresi

Palloshi

Aprigliano

et al . Angioplasty of below-the-elbow arteries in critical hand ischaemia. Eur J Vasc Endovasc Surg 2012; 43(1): 73–80.

47.

Micari

Cioppa

Vadalà

et al . Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease. JACC Cardiovasc Interv 2012; 5(3): 331–338.

48.

Chang

C-J

P-J

Hsu

L-A

et al . Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004; 43(1): 74–84.

49.

Tessitore

Endovascular versus surgical preemptive repair of forearm arteriovenous fistula juxta-anastomotic stenosis: analysis of data collected prospectively from 1999 to 2004. Clin J Am Soc Nephrol 2006; 1(3): 448–454.

50.

Asif

Gadalean

Merrill

et al . Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 2005; 67(5): 1986–1992.

51.

Cohen

Korzets

Neyman

et al . Endovascular interventions of juxtaanastomotic stenoses and thromboses of hemodialysis arteriovenous fistulas. J Vasc Interv Radiol 2009; 20(1): 66–70.

52.

Swinnen

John Zahid

Burgess

DCA

. Paclitaxel drug-eluting balloons to recurrent in-stent stenoses in autogenous dialysis fistulas: a retrospective study. J Vasc Access 2015; 16(5): 388–393.

53.

Khawaja

Cassidy

Al Shakarchi

et al . Systematic review of drug eluting balloon angioplasty for arteriovenous haemodialysis access stenosis. J Vasc Access 2016; 17(2): 103–110.

54.

Portugaller

Kalmar

Deutschmann

The eternal tale of dialysis access vessels and restenosis: are drug-eluting balloons the solution?

J Vasc Access 2014; 15(6): 439–447.

55.

Kitrou

Spiliopoulos

Karnabatidis

et al . Cutting balloons, covered stents and paclitaxel-coated balloons for the treatment of dysfunctional dialysis access. Exp Rev Med Dev 2016; 13: 121119–121126.

56.

Kitrou

Spiliopoulos

Papadimatos

et al . Paclitaxel-coated balloons for the treatment of dysfunctional dialysis access. Results from a single-center, retrospective analysis. Cardiovasc Intervent Radiol 2017; 40: 50–54.